Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of intravenous felcisetrag (TAK-954) for postoperative gastrointestinal dysfunction after bowel resection
2018-003318-42Phase 2Completed
- Sponsor
- Takeda
- Start
- Feb 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of felcisetrag in Postoperative gastrointestinal dysfunction (POGD) and feeding intolerance (3 arms), sponsored by Takeda. Primary endpoints: Time to resolution of upper and lower gastrointestinal function, Time to tolerance of solid food and 1 more. Started Feb 2019; status: completed.
02
Drugs
felcisetrag
03
Conditions
Postoperative gastrointestinal dysfunction (POGD)feeding intolerance
Beyond the preview
Go deeper on 2018-003318-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-003318-42.